TNYA

Business Context and Reporting Period

Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on developing curative therapies for heart disease. The company is an emerging growth company and a smaller reporting company. This summary covers the quarterly period ended September 30, 2025 (Q3 2025), and the nine months ended September 30, 2025 (YTD 2025).

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 22% in Q3 2025 and 21% YTD 2025 compared to the prior year periods. This reduction is primarily attributed to workforce reductions initiated in March 2025 and May 2024, resulting in lower employee-related costs, clinical support costs, and professional fees.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $4.3 million at December 31, 2024, to $56.3 million at September 30, 2025. This was driven by a follow-on equity offering in March 2025 (net proceeds of ~$48.8 million) and proceeds from warrant exercises.
• Investment Activity: The company liquidated short-term marketable securities (which were $57.1 million at year-end 2024) to fund operations, resulting in zero short-term investments as of September 30, 2025.
• Stock-Based Compensation: Stock-based compensation expense decreased to $10.3 million YTD 2025 from $12.7 million YTD 2024, reflecting the impact of workforce reductions and option repricing.

Guidance, Outlook, and Risks

• Clinical Progress:
  • TN-201 (HCM): Interim data from the MyPEAK-1 trial presented at AHA 2025 showed TN-201 was generally well-tolerated with evidence of transduction and protein expression. However, the FDA placed the trial on clinical hold in November 2025 to standardize patient monitoring and immunosuppression management. The company expects to resolve this without impacting data milestones.
  • TN-401 (ARVC): The RIDGE-1 trial is ongoing. Enrollment in the 6E13 vg/kg dose cohort is complete. Initial clinical data from Cohort 1 is expected before year-end.
• Liquidity Outlook: Management believes existing cash ($56.3 million), the $10.0 million available under the SVB Loan Agreement, and proceeds from warrant exercises ($1.9 million in October 2025) will fund operations for at least the next 12 months. Additional capital will be required to fully implement the business plan.
• Grant Funding: The company received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for the TN-401 trial, with $1.5 million recognized in the first nine months of 2025.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the potential for the FDA clinical hold to delay timelines, the need for additional financing, and the impact of workforce reductions on operational capacity.

Investor Verification Checklist

• Clinical Hold Status: Verify the timeline for resolving the FDA clinical hold on the MyPEAK-1 trial and any potential impact on the TN-201 development schedule.
• Cash Runway: Confirm the burn rate post-workforce reduction and the sufficiency of the $56.3 million cash balance plus the $10 million SVB credit line to reach the next major data readout or financing event.
• Equity Dilution: Review the terms of the March 2025 follow-on offering and the outstanding warrants (Series A and B) to assess potential future dilution.
• SVB Loan Agreement: Examine the covenants and milestone requirements for the remaining tranches of the $45 million loan facility with Silicon Valley Bank.
• Workforce Reduction Impact: Assess whether the cost savings from the 2025 workforce reduction are sustainable and if they have affected the pace of clinical operations.